title: New approaches to the treatment of frontotemporal lobar degeneration.
abstract: OBJECTIVE
  Treatment approaches for frontotemporal lobar degeneration (FTLD) are rapidly evolving with improved understanding of the disease. This brief review highlights recent advances.
  
  
  RESULTS
  Early-onset dementia has a devastating impact on families and rids its victims of their most productive and rewarding years. Over the past 10 years, FTLD has emerged as the commonest cause of dementia under the age of 60 years, outstripping even Alzheimer's disease in prevalence. Remarkable progress has occurred in our understanding of FTLD both as a set of distinctive clinical syndromes and as a set of disorders with unique genetic and pathological profiles. Although there are no Food and Drug Administration-approved medications for FTLD, new evidence of specific genetic and neurochemical defects is beginning to provide a strong rationale for pharmacological treatment.
  
  
  CONCLUSIONS
  Behavioral changes, which are common in behavioral variant frontotemporal dementia and semantic dementia, often respond to treatment with selective serotonin reuptake inhibitors. Memantine also holds promise to treat neuropsychiatric symptoms, but more prospective trials are needed.With better understanding of pathogenic molecular pathways involving microtubule-associated protein tau, progranulin and TDP-43, potential disease-modifying therapies are being studied in animal models and approaching human trials.
authors.affiliation: Department of Neurology, Memory and Aging Center, University of California, San Francisco, California 94143-1207, USA. kvossel@memory.ucsf.edu
authors.forename: Keith A
authors.initials: KA
authors.lastname: Vossel
authors.forename: Bruce L
authors.initials: BL
authors.lastname: Miller
mesh_terms: D000818:Animals; D004268:DNA-Binding Proteins / Q000235:genetics; D003704:Dementia / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology / Q000523:psychology; D018691:Excitatory Amino Acid Antagonists / Q000627:therapeutic use*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics; D008559:Memantine / Q000627:therapeutic use*; D000077153:Progranulins; D024801:Tauopathies
chemical_list: D004268:DNA-Binding Proteins; D018691:Excitatory Amino Acid Antagonists; C492314:GRN protein, human; D036341:Intercellular Signaling Peptides and Proteins; D000077153:Progranulins; D008559:Memantine